$1.58
7.60% yesterday
Nasdaq, Jun 02, 10:17 pm CET
ISIN
US81642T1007
Symbol
SLS
Sector
Industry

SELLAS Life Sciences Group, Inc. Stock price

$1.58
-0.16 9.20% 1M
+0.42 36.21% 6M
+0.54 51.92% YTD
+0.16 11.27% 1Y
-1.30 45.14% 3Y
-1.82 53.53% 5Y
-50,998.42 100.00% 10Y
Nasdaq, Closing price Mon, Jun 02 2025
-0.13 7.60%
ISIN
US81642T1007
Symbol
SLS
Sector
Industry

Key metrics

Market capitalization $157.65m
Enterprise Value $129.25m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 5.17
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-27.93m
Free Cash Flow (TTM) Free Cash Flow $-33.71m
Cash position $28.40m
EPS (TTM) EPS $-0.30
P/E forward negative
Short interest 8.87%
Show more

Is SELLAS Life Sciences Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

SELLAS Life Sciences Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a SELLAS Life Sciences Group, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a SELLAS Life Sciences Group, Inc. forecast:

Buy
100%

Financial data from SELLAS Life Sciences Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
25% 25%
-
- Research and Development Expense 17 17
22% 22%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -28 -28
23% 23%
-
Net Profit -27 -27
24% 24%
-

In millions USD.

Don't miss a Thing! We will send you all news about SELLAS Life Sciences Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SELLAS Life Sciences Group, Inc. Stock News

Neutral
GlobeNewsWire
about 20 hours ago
- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company foc...
Neutral
GlobeNewsWire
14 days ago
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Dr. Angelos Stergiou, President and Chief Executive Officer of SELLAS, will participate in a fireside chat at the A.G.P. ...
Neutral
GlobeNewsWire
19 days ago
- First ASXL1 Pediatric Acute Myeloid Leukemia (AML) Patient Dosed at MD Anderson Cancer Center: Program Supported by Rare Pediatric Disease Designation (RPDD) - First ASXL1 Pediatric Acute Myeloid Leukemia (AML) Patient Dosed at MD Anderson Cancer Center: Program Supported by Rare Pediatric Disease Designation (RPDD)
More SELLAS Life Sciences Group, Inc. News

Company Profile

SELLAS Life Sciences Group, Inc. engages in the development and commercialization of immunotherapeutics for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Head office United States
CEO Angelos Stergiou
Employees 15
Founded 2006
Website www.sellaslifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today